Blood Res.  2015 Mar;50(1):40-45. 10.5045/br.2015.50.1.40.

SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation

• Shin SH
• Lee JY
• Lee TH
• Park SH
• Yahng SA
• Yoon JH
• Lee SE
• Cho BS
• Lee DG
• Kim YJ
• Lee S
• Min CK
• Cho SG
• Kim DW
• Lee JW
• Min WS
• Park CW
• Kim HJ

• KMID: 1787911
• DOI: http://doi.org/10.5045/br.2015.50.1.40

Abstract

BACKGROUND
The expression of the SOCS genes in cytomegalovirus (CMV) viremia after hematopoietic stem cell transplantation (HSCT) remains largely unexplored.
METHODS
Using quantitative RT-PCR of mononuclear cells, we conducted pairwise comparison of SOCS1 and SOCS3 expression levels among a healthy donor group (N=55), a pre-HSCT group (N=17), and the recipient subgroup (N=107), which were divided according to the occurrence of CMV viremia and acute graft-versus-host disease (aGVHD).
RESULTS
Compared to that in the healthy donor group, SOCS1 expression was higher in the CMV+ subgroup, especially in the CMV+GVHD- group, but decreased in the other subgroups. When compared to the expression in the pre-HSCT group, SOCS1 expression was significantly higher in the CMV+ subgroup, especially in the CMV+GVHD+ subgroup. Meanwhile, compared to that in the healthy donor group, SOCS3 expression was significantly lower in all other groups. The CMV-GVHD- subgroup showed significantly lower SOCS3 expression compared to the CMV+ subgroup, the CMV+GVHD+ subgroup, and the CMV+GVHD- subgroup.
CONCLUSION
We report differential expression of SOCS genes according to CMV viremia with acute GVHD occurrence after HSCT, suggesting that regulation of SOCS expression is associated with CMV viremia.

Keyword

Suppressor of cytokine signaling (SOCS) 1 and 3; Cytomegalovirus (CMV) viremia; Quantitative real-time PCR; Allogeneic HSCT; GVHD

MeSH Terms

Cytomegalovirus*
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation*
Humans
Tissue Donors
Viremia*

Figure

• 

  Fig. 1 Comparison of (A) SOCS1 and (B) SOCS3 gene expression levels in the healthy donor group, the pre-HSCT group, and the recipients. Mononuclear cells from recipients were isolated and subjected to real-time quantitative reverse transcription-polymerase chain reaction. Relative gene expression (RE) was normalized to that of ABL1. Error bars indicate±standard error.

Reference

1. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009; 22:76–98. PMID: 19136435.

2. Mir MA, Battiwalla M. Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Mycopathologia. 2009; 168:271–282. PMID: 19156534.

3. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008; 5:47. PMID: 18371229.

4. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol. 2006; 177:7094–7102. PMID: 17082626.

5. Auletta JJ, Deans RJ, Bartholomew AM. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood. 2012; 119:1801–1809. PMID: 22228625.

6. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007; 7:454–465. PMID: 17525754.

7. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol. 2003; 4:1169–1176. PMID: 14639467.

8. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002; 17:583–591. PMID: 12433365.

9. Hodge-Dufour J, Marino MW, Horton MR, et al. Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc Natl Acad Sci U S A. 1998; 95:13806–13811. PMID: 9811882.

10. Fenner JE, Starr R, Cornish AL, et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol. 2006; 7:33–39. PMID: 16311601.

11. Yasukawa H, Ohishi M, Mori H, et al. IL-6 induces an antiinflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003; 4:551–556. PMID: 12754507.

12. El Kasmi KC, Holst J, Coffre M, et al. General nature of the STAT3-activated anti-inflammatory response. J Immunol. 2006; 177:7880–7888. PMID: 17114459.

13. Croker BA, Krebs DL, Zhang JG, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol. 2003; 4:540–545. PMID: 12754505.

14. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945–956. PMID: 16338616.

15. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15:825–828. PMID: 7581076.

16. Lee TH, Lee JY, Park S, et al. Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Res. 2013; 48:16–23. PMID: 23589790.

17. Choi SM, Lee DG, Lim J, et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. J Korean Med Sci. 2009; 24:571–578. PMID: 19654935.

18. Yoon JH, Kim HJ, Shin SH, et al. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML. Eur J Haematol. 2013; 91:112–121. PMID: 23672350.

19. Hill GR, Kuns RD, Raffelt NC, et al. SOCS3 regulates graft-versus-host disease. Blood. 2010; 116:287–296. PMID: 20435883.

20. Reddy PN, Sargin B, Choudhary C, et al. SAL). SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. Blood. 2012; 120:1691–1702. PMID: 22517899.

21. Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene. 2007; 26:6738–6749. PMID: 17934482.

22. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006; 71:154–163. PMID: 16765457.

23. Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013; 121:3745–3758. PMID: 23435462.

24. Alonso Arias R, Moro-García MA, Echeverría A, Solano-Jaurrieta JJ, Suárez-García FM, López-Larrea C. Intensity of the humoral response to cytomegalovirus is associated with the phenotypic and functional status of the immune system. J Virol. 2013; 87:4486–4495. PMID: 23388717.

25. Trilling M, Le VT, Rashidi-Alavijeh J, et al. "Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells. J Immunol. 2014; 192:447–458. PMID: 24319264.

26. Cantoni N, Hirsch HH, Khanna N, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010; 16:1309–1314. PMID: 20353832.

27. Blalock EL, Chien H, Dix RD. Murine cytomegalovirus downregulates interleukin-17 in mice with retrovirus-induced immunosuppression that are susceptible to experimental cytomegalovirus retinitis. Cytokine. 2013; 61:862–875. PMID: 23415673.

28. Osarogiagbon RU, Defor TE, Weisdorf MA, Erice A, Weisdorf DJ. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol Blood Marrow Transplant. 2000; 6:280–288. PMID: 10871153.

29. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001; 19:378–387. PMID: 11553846.

30. Sakamoto H, Yasukawa H, Masuhara M, et al. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood. 1998; 92:1668–1676. PMID: 9716595.